Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Mesoblast Limited — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.67 (market cap $141.25M), while Mesoblast Limited trades at $14.25 (market cap $1.75B). The key difference: Mesoblast Limited is far larger — about 12.4× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and ProShares UltraShort Bloomberg Natural Gas ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and Mesoblast Limited for 15 Days on average.
| KOLD | MESO | |
|---|---|---|
Market Cap | $141.25M | $1.75B |
Volume | 5,492,367 | 239,027 |
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $20.96 |
52-Week Low | $13.58 | $13.19 |
Typical Hold Time | 10 Days | 15 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD is trading at $24.475, down 1.47% on the day, with a bearish technical outlook as moving averages signal strong selling pressure. The stock faces headwinds from record-high natural gas production and mild weather forecasts that are weighing on energy sector sentiment. Recent news highlights geopolitical tensions in the Middle East and supply dynamics affecting natural gas markets, creating volatility for energy-related investments.
The outlook remains cautious given the bearish technical indicators and fundamental pressures from oversupply conditions in natural gas markets. Investment opportunities exist for contrarian investors betting on geopolitical risk premiums, but risks include continued production growth and weather-dependent demand uncertainty that could pressure energy sector performance in the near term.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
